In Brief: Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Perrigo: Sales are up 5.5% to $223.8 mil. and net income rises 23.2% to $13.2 mil. in the first quarter ended Sept. 30. OTC sales, led by "strong growth" in cough/cold remedies and antacids, were up over last year, Perrigo notes. Nutritional product sales were "very strong," with double-digit increases in vitamins and nutritional drinks, the firm says, adding that new products such as naproxen sodium and its line of "super vitamins" also contributed to the gains...